Connect Biopharma Holdings Ltd
CNTB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001835268
No open-market purchases or sales by Connect Biopharma Holdings Ltd insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $33.1M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Connect Biopharma Holdings Ltd as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −2 vs. Q2 2023
- Shares held
- 10.1M
- −279.7K (−2.7%) vs. Q2 2023
- Total value
- $8.22M
- −$3.46M (−29.6%) vs. Q2 2023
- New holders
- 1
- 3 more added
- Sold out
- 3
- 2 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNTB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 56 | $33.1M |
| Q1 2026 | 41 | $32.4M |
| Q4 2025 | 29 | $23.9M |
| Q3 2025 | 16 | $2.45M |
| Q2 2025 | 17 | $2.40M |
| Q1 2025 | 13 | $1.56M |
| Q4 2024 | 14 | $4.37M |
| Q3 2024 | 11 | $4.23M |
| Q2 2024 | 12 | $4.52M |
| Q1 2024 | 12 | $6.87M |
| Q4 2023 | 15 | $8.40M |
| Q3 2023 | 14 | $8.22M |
| Q2 2023 | 16 | $11.7M |
| Q1 2023 | 16 | $10.9M |
| Q4 2022 | 20 | $9.60M |
| Q3 2022 | 25 | $16.4M |
| Q2 2022 | 29 | $13.0M |
| Q1 2022 | 28 | $53.4M |
| Q4 2021 | 29 | $87.4M |
| Q3 2021 | 20 | $467.5M |
| Q2 2021 | 16 | $372.4M |
| Q1 2021 | 26 | $284.6M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Connect Biopharma Holdings Ltd; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 6,991,003 | $5.73M | 0.11% | 00.0% | Unchanged |
| BlackRock Inc. | 1,125,262 | $921.6K | 0.00% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 650,000 | $532.4K | 0.00% | 00.0% | Unchanged |
| UBS Oconnor LLC | 603,900 | $468.6K | 0.01% | 00.0% | Unchanged |
| Kynam Capital Management, LP | 535,005 | $434.0K | 0.07% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 97,000 | $79.0K | 0.00% | +1,500+1.6% | Added |
| JPMorgan Chase & Co | 23,532 | $18.2K | 0.00% | −24,840−51.4% | Reduced |
| Geode Capital Management, LLC | 19,032 | $14.8K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 17,219 | $14.1K | 0.00% | −6,367−27.0% | Reduced |
| Rhumbline Advisers | 16,520 | $12.8K | 0.00% | +6,585+66.3% | Added |
| Qube Research & Technologies Ltd | 46 | $36 | 0.00% | +46 | New |
| FMR LLC | 24 | $18 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 255 | $0 | 0.00% | +220+628.6% | Added |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −219,501−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −26,867−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −10,470−100.0% | Sold out |